Agios Pharmaceuticals (NASDAQ: AGIO) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Agios Pharmaceuticals to similar businesses based on the strength of its valuation, analyst recommendations, earnings, dividends, risk, profitability and institutional ownership.

Analyst Ratings

This is a summary of recent ratings for Agios Pharmaceuticals and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agios Pharmaceuticals 0 1 11 0 2.92
Agios Pharmaceuticals Competitors 866 3223 11693 232 2.71

Agios Pharmaceuticals presently has a consensus target price of $75.70, indicating a potential upside of 45.24%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.84%. Given Agios Pharmaceuticals’ peers higher possible upside, analysts clearly believe Agios Pharmaceuticals has less favorable growth aspects than its peers.

Profitability

This table compares Agios Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Agios Pharmaceuticals -506.39% -69.64% -43.12%
Agios Pharmaceuticals Competitors -5,993.97% -219.09% -39.48%

Valuation and Earnings

This table compares Agios Pharmaceuticals and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Agios Pharmaceuticals $69.89 million -$198.47 million -8.31
Agios Pharmaceuticals Competitors $284.49 million $33.78 million 74.78

Agios Pharmaceuticals’ peers have higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Agios Pharmaceuticals has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals’ peers have a beta of 8.49, suggesting that their average share price is 749% more volatile than the S&P 500.

Insider & Institutional Ownership

94.4% of Agios Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Agios Pharmaceuticals peers beat Agios Pharmaceuticals on 7 of the 12 factors compared.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

Receive News & Stock Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related stocks with our FREE daily email newsletter.